We present a cytogenetically normal neonate who developed transient abnormal myelopoiesis. The blasts showed trisomy 21. In contrast, fibroblasts, and PHA-stimulated peripheral blood demonstrated normal diploid line on extensive karyotyping. Direct sequencing of the DNA derived from the peripheral blood at overt disease revealed splice site mutation in the boundary of GATA1 exon 2. The patient received three courses of chemotherapy leading to complete remission. During the complete remission, there was neither mutation of GATA1 exon 2 nor trisomy 21, confirming somatic nature of both abnormalities. The patient is now free from the disease 12 months after remission. This case emphasizes the significance of trisomy 21 as the cause of transient abnormal myelopoiesis in Down syndrome.
Transient abnormal myelopoiesis GATA1 Trisomy 21
This is a preview of subscription content, log in to check access.
We thank Dr. Alan H. Turner, School of Medical Sciences, RMIT University, Melbourne, Australia and Ms. Yuko Kasai for reviewing the manuscript. This work was supported by Ibaraki Cancer Investigation Fund.
Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 1993;15:392–9.PubMedGoogle Scholar
Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–52.CrossRefPubMedGoogle Scholar
Cabelof DC, Patel HV, Chen Q, et al. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood. 2009;114:2753–63.PubMedGoogle Scholar
Harigae H, Xu G, Sugawara T, Ishikawa I, Toki T, Ito E. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood. 2004;103:3242–3.CrossRefPubMedGoogle Scholar
Richards M, Welch J, Watmore A, Readett D, Vora AJ. Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down’s syndrome. Arch Dis Child Fetal Neonatal Ed. 1998;79:F215–7.CrossRefPubMedGoogle Scholar
Polski JM, Galambos C, Gale GB, et al. Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate. J Pediatr Hematol Oncol. 2002;24:50–4.CrossRefPubMedGoogle Scholar
Apollonsky N, Shende A, Ouansafi I, et al. Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes. J Pediatr Hematol Oncol. 2008;30:860–4.CrossRefPubMedGoogle Scholar
Sandoval C, Pine SR, Guo Q, et al. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Pediatr Blood Cancer. 2005;44:85–91.CrossRefPubMedGoogle Scholar
Cushing T, Clericuzio CL, Wilson CS, et al. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr. 2006;148:687–9.CrossRefPubMedGoogle Scholar
Carpenter E, Valverde-Garduno V, Sternberg A, et al. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol. 2005;128:548–51.CrossRefPubMedGoogle Scholar
Magalhães IQ, Splendore A, Emerenciano M, et al. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol. 2005;27:50–2.CrossRefPubMedGoogle Scholar
Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981–6.CrossRefPubMedGoogle Scholar
Mercher T, Coniat MB, Monni R, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci USA. 2001;98:5776–9.CrossRefPubMedGoogle Scholar
Hoskote A, Chessells J, Pierce C. Transient abnormal myelopoiesis (TAM) causing multiple organ failure. Intensive Care Med. 2002;28:758–62.CrossRefPubMedGoogle Scholar
Schwab M, Niemeyer C, Schwarzer U. Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis. Med Pediatr Oncol. 1998;31:159–65.CrossRefPubMedGoogle Scholar
Rizzari C, Malberti R, Dell’Orto M, et al. Transient myeloproliferative disorder associated with trisomy 21: is a short course of chemotherapy indicated in patients with liver impairment and severe clinical problems? Med Pediatr Oncol. 1999;32:453–4.CrossRefPubMedGoogle Scholar
Chou ST, Opalinska JB, Yao Y, et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 2008;112:4503–6.CrossRefPubMedGoogle Scholar
Groet J, Mulligan C, Spinelli M, et al. Independent clones at separable stages of differentiation, bearing different GATA1 mutations, in the same TMD patient with Down syndrome. Blood. 2005;106:1887–8.CrossRefPubMedGoogle Scholar
Kanegane H, Watanabe S, Nomura K, et al. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome. Int J Hematol. 2007;86:250–2.CrossRefPubMedGoogle Scholar
Hellebostad M, Carpenter E, Hasle H, Mitchell C, Vyas P. GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with Down syndrome; implications for leukemogenesis. J Pediatr Hematol Oncol. 2005;27:408–9.CrossRefPubMedGoogle Scholar